Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

May 18, 2017May 18, 2017

X-Chem, Vertex to Jointly Develop Small Molecules for CF, Other Severe Genetic Diseases

cystic fibrosis, News

X-Chem Pharmaceuticals and Vertex Pharmaceuticals will jointly develop small molecules targeting cystic fibrosis (CF) and other severe genetic diseases. Under the collaboration announced May 16, X-Chem will apply its proprietary DEX libraries — which holds ... Read more

May 16, 2017May 16, 2017

Dalton, Arch Plan Joint Production of AB569 for Clinical Trials Involving Treatment-resistant Lung Infections

cystic fibrosis, News

Dalton and Arch Biopartners are partnering to manufacture AB569 for clinical trials involving cystic fibrosis (CF) patients with chronic, antibiotic-resistant bacterial lung infections. Under the agreement, the two will divide manufacturing ... Read more

May 10, 2017May 10, 2017

AeroVanc Inhaled Powder for Cystic Fibrosis Infections Receives US and Canadian Patents

cystic fibrosis, News

Savara has received U.S. and Canadian patents for its AeroVanc powdered, inhaled formulation of the antibiotic vancomycin hydrochloride, which combats treatment-resistant lung infections in cystic fibrosis (CF) patients. AeroVanc addresses the growing challenge of the methicillin-resistant Staphylococcus aureus (MRSA) ... Read more

May 5, 2017May 5, 2017

15 Non-profits in 7 Countries Win Vertex Grants for Cystic Fibrosis Projects

cystic fibrosis, News

Fifteen non-profit groups in seven countries will receive Cystic Fibrosis Circle of Care project grants totaling nearly $1 million this year, the program’s sponsor, Vertex Pharmaceuticals, announced. The grants, now in their third year, ... Read more

April 28, 2017April 28, 2017

SYNLAB and Counsyl to Offer Genetic Screening for CF, Other Inherited Diseases

cystic fibrosis, News

A new test able to screen for the risk for inherited conditions such as cystic fibrosis (CF) will be jointly commercialized by SYNLAB and Counsyl, two companies dedicated to the development of genetic screening ... Read more

April 21, 2017April 21, 2017

US and Canada Clear Phase 2 Clinical Trial of LAU-7b for Cystic Fibrosis

cystic fibrosis, News

The United States and Canada have given Laurent Pharmaceuticals a green light for a Phase 2 clinical trial of LAU-7b as a treatment for cystic fibrosis (CF) in adults. The Phase 2 ... Read more

April 18, 2017April 18, 2017

Arch Nears First Clinical Trial of AB569 as Treatment for Antibiotic-Resistant Lung Bacteria

cystic fibrosis, News

Arch Biopartners is on the verge of its first clinical trial of AB569, an inhalation treatment for antibiotic-resistant bacteria that infect the lungs of those with cystic fibrosis (CF) and ... Read more

April 11, 2017April 11, 2017

Enterprise Therapeutics Gets Cystic Fibrosis Trust Grant to Develop Innovative Treatments

cystic fibrosis, News

Enterprise Therapeutics has received a £95,000 grant from Britain’s Cystic Fibrosis Trust to develop innovative treatments for cystic fibrosis (CF). The money, equivalent to $118,000, will support the development of CF therapies based ... Read more

April 10, 2017April 10, 2017

AbbVie CF Scholarship Program Opens, Taking Applications Through May 24

cystic fibrosis, News

AbbVie is accepting applications for its 2017 AbbVie CF Scholarship program that helps to support outstanding young adults with cystic fibrosis (CF) as they pursue higher education. A total of ... Read more

April 4, 2017April 4, 2017

Corbus Therapy Anabasum Reduces Acute Pulmonary Exacerbations by Up to 75% in CF Patients

cystic fibrosis, News

Corbus Pharmaceuticals recently reported that its Phase 2 clinical trial examining multiple doses of anabasum (formerly known as JBT-101 or Resunab) compared to placebo in patients with cystic fibrosis (CF) achieved the trial’s primary ... Read more

Join our email list!